(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 2ÀÏ(3ÀÏÂ÷) : 2022-04-02±³À°ÀÏÀÚ : 2022-04-02
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 2ÀÏ(3ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : Çѹ®¼÷
¿¬¶ôó : 02-566-6031
À̸ÞÀÏ :
icksh@icksh.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 2 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í 100,000¿ø(2¿ù 28ÀϱîÁö)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-02 Room 1 09:00~09:30 AML(acute myeloid leukemia) microenvironment and FLT3 inhibitor resistance Elie Traer(Oregon Health & Science University USA)
±³À°½Ã°£ 04-02 Room 1 09:30~10:00 Targeting TP53 mutation in AML(acute myeloid leukemia) David A. Sallman(H. Lee Moffitt Cancer Center USA)
±³À°½Ã°£ 04-02 Room 1 10:00~10:30 Adaptive immune resistance and immune evasion by programmed death-1 homolog (PD-1H/VISTA) in AML(Targeting TP53 mutation in AML(acute myeloid leukemia) Tae Kon Kim(Vanderbilt University USA)
±³À°½Ã°£ 04-02 Room 1 10:30~11:15 Improving outcomes after CD19-targeted CAR T-cell therapy Jordan Gauthier(University of Washington USA)